With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.
New genetic studies are providing insights into the molecular changes that occur as benign moles transition to melanoma and spread to other parts of the body by metastasis.
Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.
A targeted sequencing analysis of 42 pancreatic ductal adenocarcinoma has uncovered prognostically-relevant germline mutations in 29 percent of sporadic cases.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
Three vendors applied their variant calling and interpretation pipelines to the same tumor NGS panel data and came up with overlapping but different results.
The company said it will seek FDA approval for the assay, an expanded version of FoundationACT, as a CDx for targeted therapies and as a tumor mutation profiling assay.
St. Jude Cloud, powered by DNAnexus and Microsoft, offers free access to thousands of WGS records plus cloud-based visualization and computational tools.
The lawsuits allege the company made false and/or misleading statement and/or failed to disclose information that was pertinent to investors.
The third set of papers out this week from The Cancer Genome Atlas touches on ways to cluster tumors, oncogenic processes that contribute to oncogenesis, and more.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.